**Trader consensus on no hantavirus pandemic in 2026 rests on the virus’s primary rodent-borne transmission and limited person-to-person spread.** Most strains, including those in the Americas and Eurasia, cause sporadic hantavirus pulmonary syndrome or hemorrhagic fever with renal syndrome after exposure to rodent excreta, with annual global cases typically numbering in the low thousands and no sustained community chains. The May 2026 Andes virus cluster on a cruise ship—roughly 10 confirmed cases and three deaths—highlighted the only known strain capable of limited human-to-human transmission, yet it required prolonged close contact and produced no wider outbreaks, consistent with CDC and WHO assessments of extremely low general-population risk. Historical surveillance data and current epidemiological patterns show no evidence of efficient respiratory spread or mutations enabling pandemic-scale growth. While a rare evolutionary shift enabling airborne transmission remains theoretically possible, existing conditions and monitoring indicate such a development is highly improbable before year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus pandemic in 2026?
Hantavirus pandemic in 2026?
4% chance
$17,794,077 Vol.
$17,794,077 Vol.
Dec 31, 2026
4% chance
$17,794,077 Vol.
$17,794,077 Vol.
Dec 31, 2026
This market will resolve to "Yes" if the World Health Organization explicitly characterizes Hantavirus, Hantavirus Pulmonary Syndrome (HPS), Hemorrhagic Fever with Renal Syndrome (HFRS), or a Hantavirus-related outbreak as a "pandemic" in an official public communication between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
An explicit characterization includes official WHO statements, reports, press briefings, or publications that clearly describe the outbreak as a "pandemic." A Public Health Emergency of International Concern (PHEIC) alone will not qualify unless it is also described as a pandemic.
The primary resolution source for this market will be official WHO communications. A consensus of credible reporting may also be used.**Trader consensus on no hantavirus pandemic in 2026 rests on the virus’s primary rodent-borne transmission and limited person-to-person spread.** Most strains, including those in the Americas and Eurasia, cause sporadic hantavirus pulmonary syndrome or hemorrhagic fever with renal syndrome after exposure to rodent excreta, with annual global cases typically numbering in the low thousands and no sustained community chains. The May 2026 Andes virus cluster on a cruise ship—roughly 10 confirmed cases and three deaths—highlighted the only known strain capable of limited human-to-human transmission, yet it required prolonged close contact and produced no wider outbreaks, consistent with CDC and WHO assessments of extremely low general-population risk. Historical surveillance data and current epidemiological patterns show no evidence of efficient respiratory spread or mutations enabling pandemic-scale growth. While a rare evolutionary shift enabling airborne transmission remains theoretically possible, existing conditions and monitoring indicate such a development is highly improbable before year-end.
This market will resolve to "Yes" if the World Health Organization explicitly characterizes Hantavirus, Hantavirus Pulmonary Syndrome (HPS), Hemorrhagic Fever with Renal Syndrome (HFRS), or a Hantavirus-related outbreak as a "pandemic" in an official public communication between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
An explicit characterization includes official WHO statements, reports, press briefings, or publications that clearly describe the outbreak as a "pandemic." A Public Health Emergency of International Concern (PHEIC) alone will not qualify unless it is also described as a pandemic.
The primary resolution source for this market will be official WHO communications. A consensus of credible reporting may also be used.
An explicit characterization includes official WHO statements, reports, press briefings, or publications that clearly describe the outbreak as a "pandemic." A Public Health Emergency of International Concern (PHEIC) alone will not qualify unless it is also described as a pandemic.
The primary resolution source for this market will be official WHO communications. A consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:26 AM ET
Volume
$17,794,077End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:26 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if the World Health Organization explicitly characterizes Hantavirus, Hantavirus Pulmonary Syndrome (HPS), Hemorrhagic Fever with Renal Syndrome (HFRS), or a Hantavirus-related outbreak as a "pandemic" in an official public communication between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
An explicit characterization includes official WHO statements, reports, press briefings, or publications that clearly describe the outbreak as a "pandemic." A Public Health Emergency of International Concern (PHEIC) alone will not qualify unless it is also described as a pandemic.
The primary resolution source for this market will be official WHO communications. A consensus of credible reporting may also be used.**Trader consensus on no hantavirus pandemic in 2026 rests on the virus’s primary rodent-borne transmission and limited person-to-person spread.** Most strains, including those in the Americas and Eurasia, cause sporadic hantavirus pulmonary syndrome or hemorrhagic fever with renal syndrome after exposure to rodent excreta, with annual global cases typically numbering in the low thousands and no sustained community chains. The May 2026 Andes virus cluster on a cruise ship—roughly 10 confirmed cases and three deaths—highlighted the only known strain capable of limited human-to-human transmission, yet it required prolonged close contact and produced no wider outbreaks, consistent with CDC and WHO assessments of extremely low general-population risk. Historical surveillance data and current epidemiological patterns show no evidence of efficient respiratory spread or mutations enabling pandemic-scale growth. While a rare evolutionary shift enabling airborne transmission remains theoretically possible, existing conditions and monitoring indicate such a development is highly improbable before year-end.
This market will resolve to "Yes" if the World Health Organization explicitly characterizes Hantavirus, Hantavirus Pulmonary Syndrome (HPS), Hemorrhagic Fever with Renal Syndrome (HFRS), or a Hantavirus-related outbreak as a "pandemic" in an official public communication between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
An explicit characterization includes official WHO statements, reports, press briefings, or publications that clearly describe the outbreak as a "pandemic." A Public Health Emergency of International Concern (PHEIC) alone will not qualify unless it is also described as a pandemic.
The primary resolution source for this market will be official WHO communications. A consensus of credible reporting may also be used.
An explicit characterization includes official WHO statements, reports, press briefings, or publications that clearly describe the outbreak as a "pandemic." A Public Health Emergency of International Concern (PHEIC) alone will not qualify unless it is also described as a pandemic.
The primary resolution source for this market will be official WHO communications. A consensus of credible reporting may also be used.
Volume
$17,794,077End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:26 AM ETResolver
0x65070BE91...**Trader consensus on no hantavirus pandemic in 2026 rests on the virus’s primary rodent-borne transmission and limited person-to-person spread.** Most strains, including those in the Americas and Eurasia, cause sporadic hantavirus pulmonary syndrome or hemorrhagic fever with renal syndrome after exposure to rodent excreta, with annual global cases typically numbering in the low thousands and no sustained community chains. The May 2026 Andes virus cluster on a cruise ship—roughly 10 confirmed cases and three deaths—highlighted the only known strain capable of limited human-to-human transmission, yet it required prolonged close contact and produced no wider outbreaks, consistent with CDC and WHO assessments of extremely low general-population risk. Historical surveillance data and current epidemiological patterns show no evidence of efficient respiratory spread or mutations enabling pandemic-scale growth. While a rare evolutionary shift enabling airborne transmission remains theoretically possible, existing conditions and monitoring indicate such a development is highly improbable before year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions